THE INTERACTION STUDY OF THE ORAL HYPOGLYCEMIC AGENTS WITH RIFAMPICIN IN TUBERCULOSIS PATIENTS WITH DIABETES MELLITUS

Background: Tuberculosis remains a foremost cause of morbidity and mortality in developing countries.Diabetes mellitus boosts the risk of active tuberculosis.DM management in patients with TB is also problematic.TB drug rifampicin increases the consent of most oral antidiabetic drugs that are generally used in low-income to middle-income countries, sulfonylureas are metabolized in the liver by CYPP450 enzymes, from which rifampicin is a virtuous inducer.To overcome the properties of rifampicin in dealing with and maintaining glycaemic control, metformin has been recommended as a better choice over other oral hypoglycaemic agents for the reason that it is not metabolized in the liver. Moreover, metformin is the primary choice antidiabetic according to type 2 DM treatment strategies.There is very inadequate data on the concomitant use of metformin and rifampicin and the essential for dose modifications in patients with TB-DM.In healthy volunteers, rifampicin produced altered oral hypoglycaemic agents' absorption kinetics, foremost to higher exposure levels and improved glucoselowering action.Hence there is a prerequisite to comprehend the effect of Oral hypoglycaemic agents when co-administered with rifampicin.Method: The study is shown in the pulmonologist department.The study participants were included based on the study principles.The data is collected after obtaining the informed consent.Demographic data, clinical history, diagnosis, and investigations were documented in a pre-formed questionnaire.The subjects who are being treated with oral hypoglycaemic drugs and rifampicin were analysed for the